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I nclinicalpractice themaximofOccam’s razor isoftenadopted,1such that,wheneverpossible, a singlediagnosis is favoredovermultiplediagnoses.Rarediseaseshavea frequencyof less than
1 in 2000,2 and statistically the chances of an individual being af-
fected by 2 or more rare diseases would seem to be remote. How-
ever,withmore than6000rarediseases andup to6%to8%of the
Europeanpopulationestimatedtoexperiencea rarediseaseat some
time in their lifetime,2 there is potential for 2 ormore rare disorders
to occur by chance. This scenario has been reported in various con-
stitutional disorders with both distinct and overlapping pheno-
types, including familial neoplasia and/orpatientswithmultiplepri-
mary tumors. If Occam’s razor is applied, then the detection of a
mutation in a specific inherited cancer genemight lead the clinician
to attribute any tumors that are not typical features of the relevant
inherited cancer syndrome to examples of variable phenotypic ex-
pressionor coincidence. In such circumstances, thepatientmay re-
ceive suboptimal treatment and the estimated cancer risks to rela-
tives could be erroneous. In addition, studies of patients harboring
multiplemutations indifferent familial cancer syndromegenescould
provide insights into how the function of the relevant gene prod-
ucts may be related, for example, if a particular combination re-
sulted in amorepronouncedor novel phenotype (analogous to the
differences in phenotype between patients with monoallelic and
biallelic mismatch repair gene mutations3). The best-known
examples of patients with multiple inherited cancer gene muta-
tionsare reportsofpatientswithmutations inBRCA1andBRCA2.4-22
Interestingly, thephenotype in thesepatientshasgenerallynotbeen
shown to bemore severe than when a single mutation is present.
Herein we report 5 new cases withmultiple pathogenic germ-
line mutations in rare inherited cancer syndrome genes. Three in-
volve the combination of mutations in FLCN with NF1, TP53, and
MSH2, respectively, 1 inMLH1andXPA,andthefifth inNF1andBRCA2.
In addition, we reviewed the published literature to identify other
cases and provide a summary of the published experience to date.
We suggest that this phenomenon will be increasingly recognized
and careful descriptions of such cases will inform the treatment of
similar patients.
Reports of Cases
Written informed consent was obtained for all case reports
described herein.
Case 1
A 39-year-oldman presentedwith testicular seminoma, and a rou-
tine abdominal scan 4 years later revealed a pheochromocytoma.
Following his seminoma diagnosis, he also developed a pneumo-
Mendelian causes of inherited cancer susceptibility are mostly rare and characterized by
variable expression and incomplete penetrance. Phenotypic variability may result from a
range of causes including locus heterogeneity, allelic heterogeneity, genetic and
environmental modifier effects, or chance. Another potential cause is the presence of
2 or more inherited cancer predisposition alleles in the same individual. Although the
frequency of such occurrences might be predicted to be low, such cases have probably been
underascertained because standard clinical practice has been to test candidate inherited
cancer genes sequentially until a pathogenic mutation is detected. However, recent advances
in next-generation sequencing technologies now provide the opportunity to perform
simultaneous parallel testing of large numbers of inherited cancer genes. Herein we provide
examples of patients who harbor pathogenic mutations in multiple inherited cancer genes
and review previously published examples to illustrate the complex genotype-phenotype
relationships in these cases. We suggest that clinicians should proactively consider the
likelihood of this phenomenon (referred to herein as multilocus inherited neoplasia alleles
syndrome [MINAS]) in patients with unusual inherited cancer syndrome phenotypes.
To facilitate the clinical management of novel cases of MINAS, we have established
a database to collect information on what is likely to be an increasingly recognized cohort
of such individuals.
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thorax andwent on to have 6 further occurrences. At age 55 years
he complained of abdominal/back pain, and a computed tomo-
graphic scan revealed bilateral renal masses that were demon-
strated to be renal cell carcinomas (RCCs) following removal. Rein-
vestigation following further episodes of abdominal pain identified
2 gastrointestinal stromal tumors (GISTs). At age 56 years, a com-
puted tomographic lung scan (to investigate a pneumothorax) re-
vealed a malignant peripheral nerve sheath tumor (MPNT). Skin
examination revealed multiple skin neurofibromas, 2 café-au-lait
patches, andaxillary frecklingbutno fibrofolliculomas.A clinical di-
agnosis of neurofibromatosis type 1 (NF1) wasmade, and although
thiswas considered tobe the causeof hisMPNTandpossiblypheo-
chromocytoma and GIST, the history of renal cancers and recur-
rent pneumothorax were considered unrelated.
Next-generation sequencing of 94 inherited cancer geneswas
performed using the Illumina TruSight cancer panel.23 A previously
reportedsplicesitemutation inFLCN (c.1062 + 2T>G)24,25andanon-
sense mutation in NF1 (c.1381C>T p.[Arg461*]) were detected and
confirmed by means of Sanger sequencing. FLCNmutations cause
Birt-Hogg-Dube (BHD) syndrome, a rare condition in which af-
fected individuals are predisposed to RCC, pulmonary cysts and
pneumothoraces, and fibrofolliculomas. A first-degree relative had
also received a diagnosis of bilateral chromophobe RCCs at age 45
years andwas found to have facial fibrofolliculomas but did not un-
dergo genetic testing. Presence of the FLCNmutationwas demon-
strated in a further first- and second-degree relative, butbothwere
asymptomatic with normal renal scan results. It was also identified
in a second-degree relative with numerous fibrofolliculomas and a
historyof recurrentpneumothorax (2occurrences).Anobligatecar-
rier in the familyhadpancreatic adenocarcinomabutwasnotknown
tohave features ofBHDsyndromeduring life, althoughautopsy re-
vealed bilateral renal oncocytomas. There was no known family
history of NF1.
Neurofibromatosis type 1 has a population frequency of 23 per
100 00026 andmightbeexpected toexist in combinationwith an-
other inherited cancer syndrome only rarely, although phenotypic
variability and use of clinical diagnostic criteria (rather than genetic
testing) may underestimate this. It is associated with predisposi-
tion to a variety of neoplasms including pheochromocytoma, GIST,
carcinoid tumor, cutaneous/plexiform neurofibromas, and MPNT.
Thus, in this caseassociatedwith2pathogenic inheritedcancer syn-
dromegenemutations, theoccurrenceof theMPNT,pheochromo-
cytoma,GIST,andRCCcanbeexplainedbut testicular seminomahas
not been associated with mutations in either gene.27,28 This sug-
gests that the seminomamight be a consequence of the combina-
tion of FLCN and NF1mutations (seminoma has been linked to ab-
errations in thec-kit,RAS/mitogen-activatedproteinkinase [MAPK],
and phosphatidylinositol 3-kinase [PI3K]/AkT pathways,29 and the
NF1 and FLCN gene products regulate RAS/MAPK and mammalian
target of rapamycin [mTOR]/PI3K/Akt signaling, respectively29,30)
or be coincidental, testicular being the most common solid tumor
amongmen aged 15 to 34 years.31
Case 2
A32-year-oldmanpresentedwithdysphagia.Hehadahistoryoful-
cerative colitis for which he had undergone a panprotocolectomy
at age 27 years; pathological examination of the colectomy speci-
men had revealed an incidental rectal adenocarcinoma. Endos-
copy revealed a gastroesophageal junction adenocarcinoma, and
staging imaging demonstrated a 6-cm left kidney tumor. Biopsy of
the latter suggestedaprimary renal neoplasm,promptingnephrec-
tomy. Histologic analysis of the resected kidney confirmed a chro-
mophobe RCC. Examination of the skin showed facial fibrofollicu-
lomas. There was no history of cancer in first-degree relatives, but
tumors in second-degree relatives included esophageal squamous
cell carcinomaat age54years, a brain tumorof uncertain histologic
subtype at 50 years, and an oropharyngeal carcinoma at 49 years.
Genetic investigations revealed 2 pathogenic mutations in
FLCN (c.715C>Tp.[Arg239Cys])32andTP53 (c.526T>Cp.[Cys176Arg]).
The latter has been reported as a somatic mutation on multiple
occasions,33,34 including incolorectaladenocarcinoma,33butnotpre-
viously in germline samples.34 It is rare and does not appear in the
ExAC data set.35 In silico tools predict a damaging or function-
altering effect.36-38 No other family members were available for
genetic testing.
Kidney tumors, typically with a hybrid chromophobe/
oncocytic RCC histopathologic profile, are a major feature of BHD
syndrome. Renal cell carcinoma has been reported in TP53muta-
tion carriers, although no firm association been made.39 The rela-
tionship between colorectal cancer and BHD syndrome is
controversial,24,40butan increasedriskofcolorectal cancerhasbeen
reportedwithulcerative colitis (although typically in thosewithdis-
ease for>10years41) andalso inTP53mutationcarriers.Toourknowl-
edge, esophageal cancers have not been reported in FLCN muta-
tion carriers but have occurred in Li-Fraumeni syndrome families,
although again the association with this condition is not clear.39,42
We note that the median age at diagnosis of renal tumors in FLCN
mutationcarriers (48years)25 is older than theageatonsetof these
tumors in this case.
Case 3
A 53-year-old woman presented with a rectal adenocarcinoma and
had ahistory of spontaneouspneumothorax at age46years. Immu-
nohistochemicalanalysisof theproband’s rectal tumorshowednoab-
normality, but the colon cancer of a relative (who also had multiple
pneumothoraces)demonstrated lossof stainingofMSH2andMSH6
proteins. Germline genetic testing in the proband did not detect a
At a Glance
• The identification of a constitutional deleterious variant at more
than 1 locus associated with inherited neoplasia has substantial
potential implications for cancer risks, but these are not readily
predictable.
• We propose the termmultilocus inherited neoplasia alleles
syndrome (MINAS) to describe such cases, which are expected
to becomemore frequently reported with increased clinical
application of next-generation sequencing.
• Five newMINAS cases are described, and a systematic literature
reviewwas undertaken, revealing 82 reported cases involving
17 genes.
• Deleterious variants appeared to act independently in many
cases, although no consistent effect was observed.
• To facilitate accurate information as to the effect of particular
deleterious variant combinations, cases have been uploaded
to a public database (phenotypic term “MINAS”) and further
cases are invited.
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pathogenic mismatch repair genemutation, but a pathogenic FLCN
mutation (c.1285delCp.[His429Thrfs*39])was identified. Three sib-
lings had phenotypic similarities to the proband. A sister developed
apneumothorax at age37years andhad facial fibrofolliculomas. She
developed endometrial cancer at 52 years. Genetic testing demon-
strated the familialFLCNmutationandanMSH2 truncatingmutation
(c.892C>T p.[Gln298*]). The twin sister of this individual had pneu-
mothoraces, RCC, and colorectal polyps. She also carried both
mutations, as did a brother with facial fibrofolliculomas.
Colorectal and endometrial cancers are characteristic of Lynch
syndromecausedbyMSH2mutations,andtheagesatdiagnosis seen
in this family are typical.43 However, the proband did not carry the
pathogenic MSH2mutation detected in her siblings and may rep-
resent a phenocopy. Also, a role of the FLCNmutation in the devel-
opment of colorectal tumors in the family cannot be excluded.24,40
Fibrofolliculomas,RCC,andpneumothoracesarenotassociatedwith
Lynch syndrome.44
Case 4
Amale proband presented with amucinous cecal cancer at age 65
yearsandametachronoussigmoidcoloncancer inhis remaining large
bowelat67years.Onefirst-degreerelativehaddevelopedcoloncan-
cer at 42 years, but there was no other family history of Lynch syn-
drome–related tumors. His parents were not knowingly consan-
guineous but were both from the same small community in India.
The proband had received a clinical diagnosis in early childhood of
xerodermapigmentosum (XP). At least 1 other first-degree relative
was known to have a similar pattern of skin tumors, but that indi-
vidual hadno internalmalignantneoplasms.Neitherparenthadany
reported skin abnormalities.Onexamination, his sun-exposed skin
showed considerable signs of UV damage (eg, severe freckling and
loss of pigment), but he had no other features of XP such as neuro-
logical or intellectual deficits. His skin tumors over the previous 20
yearshad includedasquamouscarcinoma inanactinickeratosis, sev-
eral seborrheic keratoses, 2 keratoacanthomata/squamous carci-
nomas, junctional nevi, a squamous carcinoma, and 2 lentigo ma-
lignae (premalignant melanoma). Immunohistochemical analysis
demonstrated lossofMLH1andPMS2expression inbothcoloncan-
cers. Constitutional genetic testing revealed MLH1 c.306G>T p.
(Glu102Asp) (classedas likelypathogenic45). Fibroblasts fromaskin
biopsywere tested for XP,which showed reduced levels of nucleo-
tide excision repair. He therefore did not have mild XP variant as
mightbeexpected,but ratherhadmildvariantXP-A, consistentwith
survival into his 60s. Constitutional genetics analysis revealed a
homozygousXPA intron4 splicemutation (c.555 + 8A>G).Molecu-
lar analysis of his various tumors is summarized in the Table.
Theprevalenceofmicrosatellite instability in skin tumors inXP
is unknown. A contribution of theMLH1mutation to the dermato-
logical phenotype may be suggested by the presence of microsat-
ellite instability in someof the skin tumors, but thepresenceof nor-
malMLH1andPMS2expressionarguesagainst this. Skin tumors are
associated with Lynch syndrome but these are characteristically
sebaceous in origin, which was not observed in this case.
Case 5
AwomanwithNF1, having 1 café-au-lait patch, numerous cutaneous
neurofibromas, possible Lisch nodules, and an MPNT, received a
diagnosis of a ductal breast carcinoma at age 48 years and subse-
quently went on to develop a cutaneous melanoma at 57 years.
Constitutional genetic testing revealed both NF1 c.6792C>G p.
(Tyr2264*) and BRCA2 c.5213_5216del p.(Thr1738Ilefs*2).46 Muta-
tions in both genes can be associated with breast cancer,47 but the
risk ismuchhigher forBRCA2. Thebreast cancer couldbe consistent
witheithersyndrome,andnotumoranalysiswas reportedthatcould
help determinewhich genewasmore significant in its initiation.
Having identified 5 cases harboring multilocus inherited neo-
plasia gene mutations, we proceeded to review the published lit-
erature to determine the nature and frequency of similar cases in a
systematic fashion. We propose the termmultilocus inherited neo-
plasia alleles syndrome (MINAS) to describe this phenomenon.
Literature Survey of Multilocus Inherited Neoplasia
Alleles Syndrome
Identification of Cases
To reviewpublished caseswithMINAS,we undertook a systematic
review of the published literature (see eMethods in the Supple-
ment) based on a list of inherited cancer genes (n = 94) (eTable 1 in
the Supplement).
Clinical Aspects
We identified82cases involving 17 inherited cancer genes4-7,20,48-69
(seeeTable2 in theSupplement).Thecombinationofcoexistingmu-
tations in BRCA1/BRCA2, BRCA2/TP53, BRCA1/MLH1, and APC/MLH1
were theonly combinations that occurred inmore than 1 family. This
mayreflectascertainmentbias(certaingenesarecommonlyscreened
for simultaneously), common foundermutations present in specific
populations, and the fact that hereditary breast cancer, followed by
colorectal cancer, is themost common indication for cancer genetic
assessment.70 Indeed, 13 patients had a combination of 2 of the 3
Ashkenazi founder BRCA1 and BRCA2mutations.
Table. Molecular Analysis of Tumors From Case 4
Tumor MLH1 IHC PMS2 IHC MSI Assessment
Mucinous cecal adenocarcinoma Loss Loss High
Sigmoid colon adenocarcinoma Loss Loss High
Squamous carcinoma (No. 1) Present Present Stable
Squamous carcinoma (No. 2) Present Present Stable
Lentigo maligna Present Present High
Actinic keratosis Present Present High
Squamous carcinoma in actinic keratosis Present Present High
Abbreviations:
IHC, immunohistochemistry;
MSI, microsatellite instability.
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An interesting aspect of patientswithMINAS iswhethermuta-
tions inparticular combinationsofgenesareassociatedwithamore
(or less) severephenotype(eg,earlieronsetofcancerorcancer types
not usually seen in individualswith a singlemutation). Thewide va-
riety of combinations of individual germlinemutationsmeans that,
with theexceptionofBRCA1/BRCA2, formutationcombinations the
information on phenotypic effects is limited.
Leegteetal8described 12casesof combinedBRCA1/BRCA2mu-
tation and suggested that there was no evidence of increased se-
verity, whereas Heidemann et al7 reported 8 cases and suggested
that a more severe phenotype was observed in 2. Other combina-
tions of inherited breast cancer genes havebeendescribed. For ex-
ample, a combination of mutations in BRCA1 and PALB2 was de-
scribed in a patientwithmultifocal breast cancer67 (case 25, eTable
2 in the Supplement). Uterine leiomyomas and ameningiomawere
also diagnosed, but it is impossible to know whether these were
related to a specific mutation or were coincidental.
Two reports of germline BRCA2 and TP53 mutations were
identified.53,54 In amousemodel in which the homologues of both
of thesegenesare conditionally knockedout inepithelial tissues (to
avoid embryonic lethality), a greater incidence and earlier onset of
mammary and skin carcinomas was observed in comparison with
mice inwhichonlyTrp53orBrca2wasconditionallyknockedout(with
conditional knockout/wild-type heterozygosity in the other gene),
suggestingasynergisticeffect in thesetissues.71Althoughthemouse
model is not directly comparable to the human status,more than 2
cancers had occurred in both cases of BRCA2/TP53MINAS, though
1 tumorwaswithin the radiotherapy field and the ages of diagnosis
in these cases are not atypical for mutations in either gene.39,72
The second most frequently reported examples of specific
MINAS were combinations of genes predisposing to inherited
colorectal cancers62-66 (cases 20-24, eTable 2 in the Supplement).
Interestingly, severephenotypeswerenoted in2patientswithAPC/
MLH1mutation combinations, with jejunal cancer seen in 1 case62
and accelerated polyp progression in the other.65
The phenotypic consequences of MINAS may be easier to in-
terpretwhenthe2genes involvedareassociatedwithdissimilar and
narrow phenotypes. Thus, there are various reports of a BRCA1/
BRCA2mutation in combination with a mismatch repair gene mu-
tation (see cases 1-4, eTable 2 in the Supplement). In general, these
havenotdemonstratedclearevidenceofasynergisticeffectof these
types ofmutations on the severity of the phenotype, although 1 re-
ported case with BRCA1 andMLH1mutations had a severe pheno-
type involving early-onset bilateral breast cancer, andendometrial,
ovarian, andclear-cell renal cancersdiagnosedat age39years.Both
breast tumors showed loss of the wild-type BRCA1 allele but also
showed absent staining ofMLH1 on immunohistochemical analysis
and loss of thewild-typeMLH1 allele. This suggests that both germ-
line mutations were significant in breast tumorigenesis in this pa-
tient. The high number of tumors and the development of early-
onset RCC (not usually associated with BRCA1 orMLH1mutations)
suggests a possible synergistic effect.49
Reports of other MINAS cases with specific gene combina-
tions are rare. For example,mutations in the phosphatase and ten-
sin homolog gene (PTEN), which affect the PI3K/Akt signaling
pathway,73,74 are reported incombinationwithmutations inTP53,59
APC,60 and SDHC,61 with tumors characteristic of each mutation
being observed in all 3 cases. A number of the tumors in the PTEN/
TP53 case were not typical of a mutation in either gene, and early
onset of colonic polyps andparagangliomawere noted in the other
patients. PTEN normally acts via Akt to downregulate MDM2 (and
therefore increase p53 levels) in addition to its other roles,73,74 so
this interactionmay lead to amore severe phenotype.
A further case of BRCA1 and NF1 mutations in a patient with
cutaneous features of NF1 and early-onset (35 years) breast cancer
has also been described.69 Of note is the fact that NF1 and BRCA1
are both located on the long arm of chromosome 17. The presence
of early-onset breast cancer and NF1 in the patient’s mother, along
with bothmutations being found in the proband,may suggest that
the 2 altered geneswere in cis. Such information has important im-
plications for genetic counseling of families in which multiple mu-
tations are identified although interestingly, theproband’s brother,
who also had NF1, did not carry the BRCA1mutation, suggesting a
recombination event in themother.
A case of MINAS involving FLCN and APCmutations has been
reported.56 Typical colonic polyps anda colorectal cancer at age28
yearsoccurred, aswell as recurrentpneumothoracesand facial pap-
ules. The features are consistentwith an independentmechanism,
although theauthors suggested that theFLCNmutationmighthave
enhanced the tumorigenic process given the observation that so-
matic FLCNmutations frequently occur in (microsatellite unstable)
colorectal cancers.40
Molecular Genetics Aspects
In theory, insights into the role of individual inherited cancer gene
mutations in the pathogenesis of tumor types that are rarely asso-
ciatedwith either of the relevant genes (or tumor types associated
withbothgenes)mightbederivedfromloss-of-heterozygosity (LOH)
studies (assumingtherelevant inheritedcancergenesaretumorsup-
pressorgenes[TSGs]).Loss-of-heterozygosityanalysis,however,can
be uninformative if the somatic mutation (“second hit”) is a point
mutation or promoter methylation of the wild-type allele (ie, no
LOH).5 For example, LOHanalysis of 3 primary breast cancers from
a woman with BRCA1/BRCA2MINAS demonstrated LOH at BRCA1
in 1 tumor and at BRCA2 in the other 2—suggesting that there was
no direct interaction between the 2 loci in the tumors. However, in
another case report of BRCA1/BRCA2MINAS, LOH at both loci was
demonstrated in an ovarian cancer from the same patient.19
Future Perspectives
There are inherent ascertainment biases influencing which MINAS
cases are present in the literature, including more frequent analysis
of combinations of particular genes, the range of phenotypes re-
ferred for testing, and the restrictionof analyzedgenes toonly those
most strongly suggested by the tumor history. Availability, or lack
thereof,ofanalysisofcertaingenes insomecentersmayalsobeafac-
tor and is likely to have led to recognition of 3 FLCNMINAS cases at
ourcenterwhere thisgene is tested frequently.Clinical features such
as theskinmanifestationsofBHDsyndromeandNF1can indicate the
need for analysis of specific genes, but increasinguseof cancer gene
panels or whole-exome/genome sequencing provides the opportu-
nity for a more comprehensive genetic testing strategy and is likely
to result in increased recognition of cases of MINAS. Increasing de-
tection will lead to increased demand for accurate information on
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whether particular combinationsofmutations are likely to result in a
particularlyseverephenotype(ie,asynergistic interaction)orwhether
the resulting phenotype is typical of each mutation having an inde-
pendent effect. Reviewofprevious reports ofMINAS reveals that al-
thoughamoreseverephenotypeseems likely insomecases, thiscan-
not be concluded in the majority. In utero death from more severe
manifestations of mutation combinations may account for some
milder phenotypes, but where survival occurs, MINASmay bemore
likely suspected in severecasesor thosewithanatypical phenotype.
We suggest that as further cases are uncovered by routine multi-
genetestingstrategies, thosecaseswitha less severephenotypewill
be recognizedmore easily. However, in certain circumstances itmay
beprudenttoexpectthataparticularcombinationofmutationsmight
result in a more severe phenotype. Thus, if an individual has muta-
tions inTSGsthatmaptothesamechromosomeregion, lossofachro-
mosome (or part of it) harboring the wild-type alleles will result in a
tumorhomozygousnull forbothTSGs(thismayhaveoccurred incase
2 because FLCN and TP53map to 17p11.2 and 17p13.1, respectively).
Also, if there is a direct relationship between themechanisms of tu-
morigenesis of the 2 mutations (eg, APC and mismatch repair gene
mutations), amore severephenotypemayoccur. In addition, 2 gain-
of-functionmutations in proto-oncogenesmight predict amore se-
vere phenotype (althoughwehave not found reports of such cases)
because, in contrast to TSGs, an additional event (somatic inactiva-
tion of awild-type allele) is not required to initiate tumorigenesis. As
mutation-dependent targeted therapies for the treatment of can-
cers become amore commonoption in oncology, the recognition of
MINASandapplicationoftumoranalysistodefinethemost likelydriver
mutationwill becomemore important.
Conclusions
Theoptimumresourcewithwhich todiscern theeffectsof individu-
ally rare mutation combinations and improve future management
of patients with MINAS is a reference database containing clinical,
genetic, and tumor information. Such information could guide the
clinicianastowhattheeffectofeachcombinationofmutationsmight
be. To facilitate sharing of such information, cases can be uploaded
to the Leiden Open Variant Database and identified by “MINAS”
phenotype (http://databases.lovd.nl/shared/diseases/04296).We
hope that other oncology and genetics heath care professionals
and researchers will contribute their cases in order to increase
knowledge of this emerging phenomenon.
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